Treatment of cystic fibrosis related bone disease

• Published in: Journal of clinical & translational endocrinology 2022-03, Vol.27, p.100291-100291, Article 100291
• Main Authors: Ullal, Jagdeesh, Kutney, Katherine, Williams, Kristen M., Weber, David R.
• Format: Article
• Language: English
• Subjects: Bisphosphonates; Bone density; Bone density screening; Cystic fibrosis; Cystic fibrosis bone disease; Special Issue: CF Endocrinology Advance
• ISSN: 2214-6237; 2214-6237
• DOI: 10.1016/j.jcte.2021.100291

The advent of highly effective CFTR modulator therapies has slowed the progression of pulmonary complications in people with cystic fibrosis. There is increased interest in cystic fibrosis bone disease (CFBD) due to the increasing longevity of people with cystic fibrosis. CFBD is a complex and multifactorial disease. CFBD is a result of hypomineralized bone leading to poor strength, structure and quality leading to susceptibility to fractures. The development of CFBD spans different age groups. The management must be tailored to each group with nuance and based on available guidelines while balancing therapeutic benefits to risks of long-term use of bone-active medication. For now, the mainstay of treatment includes bisphosphonates. However, the long-term effects of bisphosphonate treatment in people with CF are not fully understood. We describe newer agents available for osteoporosis treatment. Still, the lack of data behooves trials of monoclonal antibodies treatments such as Denosumab and Romozosumab and anabolic bone therapy such as teriparatide and Abaloparatide. In this review, we also summarize screening and non-pharmacologic treatment of CFBD and describe the various options available for the pharmacotherapy of CFBD. We address the prospect of CFTR modulators on bone health while awaiting long-term trials to describe the effects of these medications on bone health.